Vir Biotechnology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-04-07
- Employees
- 587
- Market Cap
- -
- Website
- http://www.vir.bio
- Introduction
Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.
Vir Biotechnology announces results from SOLSTICE trial
Vir Biotechnology's SOLSTICE Phase 2 trial showed 100% virologic response and rapid HDV RNA suppression with tobevibart and elebsiran combination in CHD patients. 80% achieved HDV RNA TND by Week 60. The company plans to initiate Phase 3 ECLIPSE program in H1 2025.
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data
Vir Biotechnology announces positive results from SOLSTICE Phase 2 trial evaluating tobevibart and elebsiran for chronic hepatitis delta, achieving 100% virologic suppression and rapid HDV RNA suppression. The combination is well-tolerated, with no severe AEs or discontinuations. Phase 3 ECLIPSE program to begin in 2025.
Related Clinical Trials:
Vir Biotechnology gets positive opinion on orphan drug designation for Tobevibar
Vir Biotechnology announced a positive opinion from the European Medicines Agency for orphan drug designation of tobevibart and elebsiran for chronic hepatitis delta, based on Phase 2 SOLSTICE trial data. 24-week data will be presented at AASLD The Liver Meeting on November 18, with an investor call scheduled for November 19.
Vir's Hepatitis Delta Drug Achieves 100% Response Rate in Phase 2 Trial
Vir Biotechnology announced positive SOLSTICE Phase 2 results for chronic hepatitis delta, showing 100% virologic response with HDV RNA suppression, undetectable virus levels in 41% at Week 24, rising to 80% by Week 60. No severe treatment-related adverse events were reported. Vir plans to initiate the Phase 3 ECLIPSE registrational program in early 2025, including three trials to evaluate the combination therapy against existing treatments.
Related Clinical Trials:
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and ...
Vir Biotechnology's SOLSTICE Phase 2 trial shows 100% virologic suppression with tobevibart and elebsiran combination for chronic hepatitis delta (CHD), with 80% achieving undetectable HDV RNA by Week 60. The combination is well-tolerated, and a Phase 3 ECLIPSE program is planned for 2025.
Related Clinical Trials:
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart
EMA's COMP issues positive opinion on orphan drug designation for tobevibart and elebsiran in chronic hepatitis delta, based on Phase 2 SOLSTICE trial data. This follows U.S. FDA fast track designation, highlighting potential in treating CHD.
Related Clinical Trials:
EMA grants orphan drug status to Vir Biotech hepatitis treatments
Vir Biotechnology's treatments for chronic hepatitis delta, tobevibart and elebsiran, received a positive opinion for orphan drug designation from the EMA. The company will present Phase 2 SOLSTICE trial data at The Liver Meeting. The orphan drug status in the EU offers incentives and market exclusivity. The FDA granted fast track designation to the combination of tobevibart and elebsiran in June 2024. Vir's financials show a strong liquidity position and positive analyst sentiment.
© Copyright 2024. All Rights Reserved by MedPath